Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

Código QR

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

Xiao-Fei Zhang, Lei Wu, Dong-Jun Wan, Ruo-Zhuo Liu, Zhao Dong, Min Chen, Sheng-Yuan Yu Department of Neurology, Chinese PLA General Hospital, Beijing, People’s Republic of China Purpose: Vilazodone is a novel serotonin (5-HT)-reuptake inhibitor and 5-HT1A partial agonist that was recentl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang XF, Wu L, Wan DJ, Liu RZ, Dong Z, Chen M, Yu SY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/cd36f614b882465a951a3c4cab6b4084
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam S, et al.
Publicado: (2016)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials
por: Yang XY, et al.
Publicado: (2018)

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
por: Berman R, et al.
Publicado: (2011)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients
por: Koshino Y, et al.
Publicado: (2013)

Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong JH, et al.
Publicado: (2015)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
por: Tobe EH
Publicado: (2013)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li G, et al.
Publicado: (2016)

Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients
por: Zou C, et al.
Publicado: (2013)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel PF, et al.
Publicado: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
por: Yang X, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
por: Diekamp B, et al.
Publicado: (2021)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
por: Han Y, et al.
Publicado: (2016)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Bernhard T Baune
Publicado: (2008)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki A, et al.
Publicado: (2014)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
por: Armaly Z, et al.
Publicado: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
por: Bojana Perovic, et al.
Publicado: (2010)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran A, et al.
Publicado: (2013)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
por: Wu MK, et al.
Publicado: (2015)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir S, et al.
Publicado: (2015)

Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: a systematic review and meta-analysis
por: Qi-Lun Lai, et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
por: Kitaichi Y, et al.
Publicado: (2013)

Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues
por: William&nbsp;V Bobo, et al.
Publicado: (2009)

Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder
por: Tsutsumi T, et al.
Publicado: (2016)

Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
por: Kawamura S,&nbsp;Maesawa C,&nbsp;Nakamura K,&nbsp;Nakayama K,&nbsp;Morita M,&nbsp;Hiruma Y,&nbsp;Yoshida T,&nbsp;Sakai A,&nbsp;Masuda T
Publicado: (2011)

Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns
por: Yi Dong, et al.

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)

Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression
por: Haybaeck J, et al.
Publicado: (2015)

Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population
por: Xie WW, et al.
Publicado: (2015)

Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
por: Charnsil C, et al.
Publicado: (2012)

The structural equation analysis of childhood abuse, adult stressful life events, and temperaments in major depressive disorders and their influence on refractoriness
por: Toda H, et al.
Publicado: (2015)